Myriad Genetics, Inc. Forecast, price target & analysts
Myriad Genetics, Inc. Target price 2026 - Analyst rating & recommendation
Myriad Genetics, Inc. Classifications & Recommendation
Myriad Genetics, Inc. Price Target
| Target Price | $4.08 |
| Price | $4.17 |
| Deviation |
2.16%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Myriad Genetics, Inc. 2027 .
The average Myriad Genetics, Inc. target price is $4.08.
This is
2.16%
register free of charge
$6.30
51.08%
register free of charge
$2.53
39.45%
register free of charge
|
|
| A rating was issued by 15 analysts: 2 Analysts recommend Myriad Genetics, Inc. to buy, 8 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2027 of
2.16%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 824.50 | 793.38 |
| 1.56% | 3.77% | |
| EBITDA Margin | -1.71% | -6.85% |
| 46.55% | 300.55% | |
| Net Margin | -44.38% | -9.36% |
| 192.00% | 78.91% |
12 Analysts have issued a sales forecast Myriad Genetics, Inc. 2026 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2026. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2026. The average Myriad Genetics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.95 | -0.78 |
| 180.14% | 80.25% | |
| P/E | negative | |
| EV/Sales | 0.51 |
11 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Myriad Genetics, Inc....
Current Myriad Genetics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Sep 01 2026 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | May 06 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Sep 01 2026 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 03 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
May 06 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
